Development and Characterization of a Novel α-Synuclein-PEST H4 Cell Line for Enhanced Drug Screening in α-Synucleinopathies
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26157205 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Nancy Carullo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Therapeutic Modalities, Pharma Research and Early Development, F. Hoffmann-La Roche Ltd., 4058 Basel, Switzerland. Hauptthemen laut MEDLINE: alpha-Synuclein, Synucleinopathies. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Roche Pharma AG (Germany), F. Hoffman-La Roche Ltd..
Abstract (Originalsprache)
Alpha-Synuclein (α-Syn) is a presynaptic neuronal protein implicated in the pathogenesis of Parkinson’s disease (PD) and other synucleinopathies, primarily through its aggregation into insoluble fibrils. The extended α-Syn half-life necessitates treatment durations that are incompatible with efficient high-throughput drug screening, can risk compound stability or cause cellular toxicity. To address this, we inserted a PEST sequence, a motif known to promote rapid protein degradation, at the C-terminus of the SNCA gene using CRISPR/Cas9 to create a novel cell line with reduced α-Syn half-life. This modification accelerates α-Syn turnover, providing a robust model for studying α-Syn dynamics and offering a platform that is applicable to other long-lived proteins. Our results demonstrate a six-fold reduction in α-Syn half-life, enabling the rapid detection of changes in protein levels and facilitating the identification of molecules that modulate α-Syn production and degradation pathways. Using inhibitors of the proteasome, transcription, and translation further validated the model’s utility in examining various mechanisms that impact protein levels. This novel cell line represents a significant advancement for studying α-Syn dynamics and offers promising avenues to develop therapeutics for α-synucleinopathies. Future research should focus on validating this model in diverse experimental settings and exploring its potential in high-throughput screening applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Therapeutic Modalities, Pharma Research and Early Development, F. Hoffmann-La Roche Ltd., 4058 Basel, Switzerland.
- Neuroscience and Rare Diseases, Pharma Research and Early Development, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.
ORCID-Profile: Nancy Carullo, Simon Gutbier, Lothar Lindemann
Förderung
- Roche Pharma AG (Germany)
- F. Hoffman-La Roche Ltd.
Zitieren
APA
Carullo, N., Haellman, V., Gutbier, S., Schlicht, S., Nguyen, T. T., Blum Marti, R., Hartz, P., Lindemann, L., & Schukur, L. (2025). Development and Characterization of a Novel α-Synuclein-PEST H4 Cell Line for Enhanced Drug Screening in α-Synucleinopathies. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26157205
Vancouver
Carullo N, Haellman V, Gutbier S, Schlicht S, Nguyen TT, Blum Marti R, et al. Development and Characterization of a Novel α-Synuclein-PEST H4 Cell Line for Enhanced Drug Screening in α-Synucleinopathies. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26157205
BibTeX
@article{Carullo2025,
author = {Carullo, Nancy and Haellman, Viktor and Gutbier, Simon and Schlicht, Sonja and Nguyen, Thien Thuong and Blum Marti, Rita and Hartz, Philippe and Lindemann, Lothar and Schukur, Lina},
title = {Development and Characterization of a Novel α-Synuclein-PEST H4 Cell Line for Enhanced Drug Screening in α-Synucleinopathies},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26157205}
}
EUVIMED